JHVEPhoto/iStock Editorial via Getty Images
- The U.S. FDA has named George Tidmarsh, a former biotech executive and adjunct professor at Stanford Medical School, to head its Center for Drug Evaluation and Research.
- He replaces Patrizia Cavazzoni, who resigned on January 18.
- Tidmarsh received his M.D. and Ph.D. — in cancer biology — from Stanford University. He also completed his pediatrics residency, as well as speciality training in pediatric oncology and neonatology at the university.
- He is also founding co-director of Stanford’s Master of Translational Research and Applied Medicine (M-TRAM) program.
- Tidmarsh founded and was CEO of Horizon Pharma, which was sold to Amgen (NASDAQ:AMGN) in 2022 for $28B.
- He has also held executive or senior positions at La Jolla Pharmaceutical Co., Threshold Pharmaceuticals, Coulter Pharmaceutical (eventually acquired by GSK), and SEQUUS Pharmaceuticals (acquired by Johnson & Johnson).
- Tidmarsh has overseen the development of seven FDA-approved drugs.
More on pharma companies
- Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
- Why Merck Is A Better Dividend Stock Than Gilead Sciences
- Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
- Dividend Roundup: Citigroup, Coca-Cola, Caterpillar, Pfizer, and more
- Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer